oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Ranigast Fast – recalled product

Ranigast Fast

HIGH 28.10.2019

contamination with N-nitrosodimethylamine (NDMA) in the active substance Ranitidinum used to manufacture the concerned batches of Ranigast Fast. Potential effects: possible carcinogenic effects and other adverse effects related to toxic contamination.

Ranigast Max – recalled product

Ranigast Max

HIGH 28.10.2019

Contamination of the active substance ranitidine with N-nitrosodimethylamine (NDMA) was found in batches of the medicinal product Ranigast Max, meaning the quality requirements are not met. Potential effects: possible toxic effects, including long-term health risks.

Mitomycin C Kyowa – recalled product

Mitomycin C Kyowa

CRITICAL 25.10.2019

Deviations were identified in the manufacturing process of the active substance, so it cannot be ensured that the products meet sterility specification requirements, which may pose a real threat to patients' health or life. Potential effects: infection, complications after intravenous administration, life‑threatening conditions.

Mitomycin C Kyowa – recalled product

Mitomycin C Kyowa

CRITICAL 25.10.2019

Due to identified deviations in the manufacturing process of the active substance, it cannot be ensured that the medicinal products made from it meet sterility specification requirements. The authority points to a potential direct threat to patients’ health or life. Potential effects: infection, severe post-injection complications, risk to health or life.

Clopidogrel Genoptim – recalled product

Clopidogrel Genoptim

MEDIUM 25.10.2019

A result outside the quality specification was found for the parameters: clopidogrel-related substances — impurity A and enantiomeric purity — impurity C, which may affect the safety and efficacy of the medicine. Potential effects: lack of treatment efficacy or adverse reactions.

TRANXENE 20 – recalled product

TRANXENE 20

CRITICAL 23.10.2019

A quality defect was identified: potential presence of visible particles in solvent ampoules of a product intended for preparation of an injectable solution. Potential effects: complications after intravenous administration, embolism, inflammatory reactions, lack of treatment safety.

AVONEX – recalled product

AVONEX

CRITICAL 18.10.2019

Suspected quality defect of the immediate packaging of the specified batches, which may result in loss of tightness and a potential risk to patients’ health or life. Potential effects: infections, complications after administration of a non-sterile drug, lack of treatment efficacy.

RANIC – recalled product

RANIC

CRITICAL 18.10.2019

Contamination of the medicinal product with trace amounts of N-nitrosodimethylamine (NDMA) in the ranitidine-containing solution for injection. Potential effects: carcinogenic and toxic effects, possible health risk.

RANITYDYNA AUROVITAS – recalled product

RANITYDYNA AUROVITAS

CRITICAL 11.10.2019

Exceedance of the acceptable limit of N-nitrosodimethylamine (NDMA) contamination was detected and confirmed in products containing Ranitidinum, creating a real, high probability of a threat to patients’ health or life. Potential effects: chronic exposure, carcinogenic effects, liver damage, general poisoning of the body.

PALIN – recalled product

PALIN

CRITICAL 11.10.2019

The European Medicines Agency decision concerned serious adverse reactions of some quinolone and fluoroquinolone antibiotics; the benefit-risk balance of products containing pipemidic acid is no longer favorable. Potential effects: serious adverse reactions, complications, risk to health or life.

MEGAPAR FORTE – recalled product

MEGAPAR FORTE

CRITICAL 02.10.2019

An error in the leaflet incorrectly specifies the maximum dose, which may lead to overdose and poses a real risk to patients’ health or life. Potential effects: paracetamol poisoning, liver damage, serious complications, life‑threatening condition.

APHTIN – recalled product

APHTIN

MEDIUM 26.09.2019

Non-compliant product odor and a decrease in active substance content were found, not meeting quality specifications. Potential effects: lack of treatment efficacy, possible adverse effects related to product degradation.

SYMBELLA – recalled product

SYMBELLA

CRITICAL 25.09.2019

The product does not meet specification requirements for the amount of ethinylestradiol released within 15 minutes, which may affect contraceptive efficacy. Potential effects: reduced effectiveness, risk of unplanned pregnancy.

SOLVERTYL – recalled product

SOLVERTYL

CRITICAL 19.09.2019

Suspicion of the presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products with Ranitidinum, which may affect human health and life and poses a potential risk to patients. Potential effects: poisoning, carcinogenic effects, systemic complications.

RIFLUX – recalled product

RIFLUX

CRITICAL 19.09.2019

Suspected presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products containing ranitidine, which may affect human health and life due to the potential toxic effects of this substance. Potential effects: possible toxic effects, complications, health risk.

RANITYDYNA AUROVITAS – recalled product

RANITYDYNA AUROVITAS

CRITICAL 19.09.2019

Suspected presence of N-nitrosodimethylamine (NDMA) contamination in medicinal products containing Ranitidinum, which may affect human health and life, posing a potential risk to patients. Potential effects: poisoning, carcinogenic effects, serious health complications.

RANIMAX TEVA – recalled product

RANIMAX TEVA

CRITICAL 19.09.2019

The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in this medicinal product, which may affect human health and life. Potential effects: increased risk of carcinogenic effects and serious threat to patients’ health and life.

RANIGAST – recalled product

RANIGAST

CRITICAL 19.09.2019

This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effect, liver damage, other toxic complications.

RANIGAST – recalled product

RANIGAST

CRITICAL 19.09.2019

The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic and other toxic effects, risk to health and life.

RANIGAST FAST – recalled product

RANIGAST FAST

CRITICAL 19.09.2019

This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: possible carcinogenic effects and other serious health disorders.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.